ERIC SCHAFER to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications ERIC SCHAFER has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.413
-
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 10; 69(10):e29812.
Score: 0.180
-
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatr Blood Cancer. 2020 02; 67(2):e28073.
Score: 0.151
-
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica. 2022 10 01; 107(10):2295-2303.
Score: 0.046
-
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 07 01; 40(19):2106-2118.
Score: 0.011
-
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol. 2022 05; 97(5):613-622.
Score: 0.011
-
Using a Bedside Algorithm to Individually Dose High-dose Methotrexate for Patients at Risk for Toxicity. J Pediatr Hematol Oncol. 2017 01; 39(1):72-76.
Score: 0.008
-
Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. Pediatr Blood Cancer. 2014 Jun; 61(6):1114-7.
Score: 0.006